Certara to Participate in Upcoming Investor Conferences
RADNOR, Pa., May 18, 2026 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader…
CertaraMay 18, 2026
Certara Reports First Quarter 2026 Financial Results
RADNOR, Pa., May 11, 2026 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader…
CertaraMay 11, 2026
Altasciences and Certara Announce Strategic Partnership to Accelerate Early Drug Development
LAVAL, Québec, and Radnor, PA — May 7, 2026 — Altasciences, a fully integrated drug…
CertaraMay 7, 2026
Certara Enters Definitive Agreement for the Sale of its Regulatory Writing and Medical Writing Business to Veristat
Transaction sharpens focus on Model-Informed Drug Development (MIDD) and Clinical Intelligence Updated 2026 guidance to…
CertaraApril 22, 2026
Certara to Report First Quarter 2026 Financial Results on May 11th, 2026
Radnor, Pa. — April 9, 2026 -- Certara, Inc. (Nasdaq: CERT), a global leader in…
Danielle PillsburyApril 9, 2026
Certara Simcyp® Simulator Results Replace Ten Human Trials for Chronic Myeloid Leukemia (CML) Therapy asciminib
Novartis used PBPK modeling for therapeutic regulatory success. They used model simulations to replace clinical…
CertaraMarch 3, 2026
Certara to Participate in Upcoming Investor Conferences
RADNOR, PA – February 27, 2026 -- Certara, Inc. (Nasdaq: CERT), a global leader in…
CertaraFebruary 27, 2026
Certara Reports Fourth Quarter 2025 Financial Results; Provides Full Year 2026 Guidance
FY 2025 Revenue of $418.8M (9% growth) and Adj. EBITDA of $134.5M (10% growth) Fourth…
CertaraFebruary 26, 2026
Certara to Report Fourth Quarter and Full Year 2025 Financial Results on February 26th, 2026
Radnor, Pa. — January 29, 2026 -- Certara, Inc. (Nasdaq: CERT), a global leader in…
CertaraJanuary 29, 2026
Certara Appoints Jon Resnick as Chief Executive Officer
Resnick brings decades of leadership experience in health sciences, business operations, strategy, innovation and commercial…
CertaraDecember 11, 2025
